Market Overview

ICYMI: Epizyme, MoviePass, And A Bull Call On Novavax

ICYMI: Epizyme, MoviePass, And A Bull Call On Novavax
Related EPZM
5 Biggest Price Target Changes For Friday
Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure
Related HMNY
Benzinga Pro's 5 Stocks To Watch Today
Benzinga's Biggest Movers For The Week Of May 7, 2018
Retirement Security: A Dividend Is Never Fake News (Seeking Alpha)

In case you missed it, here are some of Benzinga's top stories from Wednesday, Jan. 10, 2018.

Novavax Back In Favor

Shares of Novavax, Inc (NASDAQ: NVAX) got a heavy dose of upside when a bullish analyst from B. Riley FBR indicated he sees potential for the stock to trade 400 percent higher over the next 12 months. Jayson Derrick reports.


Helios and Matheson Analytics Inc (NASDAQ: HMNY) CEO in a recent interview admitted to being open to the notion of an initial coin offering for MoviePass, the movie subscription service his company is heavily invested in. To learn more, check out Wayne Duggan’s “Helios And Matheson Investors Are Loving The MoviePass ICO Talk.”

Epizyme Has Potential

Holders of Epizyme, Inc (NASDAQ: EPZM) stock saw their investment validated today by Morgan Stanley’s initiation of coverage with an Overweight rating. Get the details of the thesis in Shanthi Rexaline’s “Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making.”

Latest Ratings for EPZM

Apr 2018WedbushMaintainsOutperformOutperform
Mar 2018Leerink SwannMaintainsOutperformOutperform
Jan 2018Morgan StanleyInitiates Coverage OnOverweight

View More Analyst Ratings for EPZM
View the Latest Analyst Ratings

Posted-In: BZ ICYMIAnalyst Color News Previews After-Hours Center Analyst Ratings Media Trading Ideas Best of Benzinga


Related Articles (HMNY + EPZM)

View Comments and Join the Discussion!